Drug-induced hepatotoxicity (DIH) is an important clinical problem in the United States and
around the world. It is one of the primary reasons for failure of drug candidates during …

2592 Background: Idelalisib (IDELA) is a potent inhibitor of PI3Kδ, which has been shown to
be prominently expressed in cells of hematopoietic origin. IDELA is metabolized primarily by …

BACKGROUND & AIMS: Hepatic markers are utilized in many classification systems of
patients with hepatocellular carcinoma and, by measuring organ damage and tumor stage …

Simple Summary The incidence of hepatocellular carcinoma continues to increase
worldwide. In almost all cases, hepatocellular carcinoma develops in subjects with hepatic …

Background In a disease like unresectable hepatocellular carcinoma, overall survival is an
inadequate outcome measure for evaluating the effectiveness of treatments given the high …

The aims of this study were to identify prognostic variables for toxicity and survival in patients
with cancer participating in phase I clinical trials and compare characteristics of those …

Chemotherapy is meant to be toxic, but it is particularly aimed at the tumor cells. Collateral
damage may occur to normal cells and tissues, especially if they are fairly rapidly …

Although hepatocellular carcinoma is considered a highly lethal malignancy, recent
therapeutic advances have been achieved during the last 10 years. This scenario resulted in …

Drug-induced liver injury (DILI) in human subjects participating in clinical trials is uncommon
(1) or rare, the more serious the rarer. New drugs in development are first tested in animals …

Background/Aim: Lenvatinib is a multiple-tyrosine kinase inhibitor used to treat
hepatocellular carcinoma (HCC), and its systematic concentration varies according to liver …